Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	46.45	25.84	92.94	106.08	200.4	74.32
Short-Term Investments	20.74	25.88	149.88	264.98	300.26	184.79
Cash & Short-Term Investments	67.19	51.73	242.82	371.07	500.66	259.11
Cash Growth	-34.39%	-78.70%	-34.56%	-25.88%	93.22%	-16.32%
Accounts Receivable	1.34	34.11	40.22	0.99	-	-
Other Receivables	-	0.3	0.8	0.8	1.95	-
Receivables	1.34	34.41	41.02	1.79	1.95	-
Inventory	13.98	9.71	1.59	-	-	-
Prepaid Expenses	-	-	-	-	20.47	13.69
Restricted Cash	0.15	0.15	0.15	0.19	0.19	0.19
Other Current Assets	9.21	5.88	9.51	11.57	-	-
Total Current Assets	91.86	101.87	295.08	384.62	523.27	272.99
Property, Plant & Equipment	47.49	58.79	74.32	79.94	62.82	68.18
Other Long-Term Assets	3.36	4.84	7.02	3.57	2.03	1.77
Total Assets	142.71	165.5	376.42	468.13	588.12	342.94
Accounts Payable	2.15	3.68	6.87	17.37	7.12	7.96
Accrued Expenses	13.85	48.53	50.41	44.91	40.34	27.2
Current Portion of Leases	-	12.18	13.64	2.75	1.99	1.58
Current Unearned Revenue	116.34	77.83	8	40.76	33.46	-
Total Current Liabilities	155.98	142.23	78.92	105.79	82.9	36.74
Long-Term Leases	35.24	48.31	58.06	25.52	13.04	14.14
Long-Term Unearned Revenue	38.05	72.19	107.24	55.71	27.8	-
Other Long-Term Liabilities	3.97	2.02	5.56	1.5	2.04	1.28
Total Liabilities	233.25	264.74	249.78	188.51	125.78	52.16
Common Stock	0	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	1,951	1,870	1,822	1,745	1,587	1,109
Retained Earnings	-2,042	-1,969	-1,693	-1,465	-1,125	-817.96
Comprehensive Income & Other	0.02	-0.2	-2.07	-0.37	0.3	0.22
Total Common Equity	-90.54	-99.23	126.64	279.61	462.34	290.78
Shareholders' Equity	-90.54	-99.23	126.64	279.61	462.34	290.78
Total Liabilities & Equity	142.71	165.5	376.42	468.13	588.12	342.94
Total Debt	35.24	60.49	71.7	28.27	15.03	15.72
Net Cash (Debt)	31.95	-8.76	171.12	342.8	485.63	243.39
Net Cash Growth	-21.32%	-	-50.08%	-29.41%	99.53%	-21.24%
Net Cash Per Share	5.42	-2.07	41.94	91.49	164.13	118.59
Filing Date Shares Outstanding	7.47	4.77	3.84	3.72	3.34	2.34
Total Common Shares Outstanding	7.47	4.26	3.84	3.67	3.33	2.27
Working Capital	-64.12	-40.36	216.16	278.84	440.37	236.25
Book Value Per Share	-12.13	-23.31	33.00	76.25	138.64	127.97
Tangible Book Value	-90.54	-99.23	126.64	279.61	462.34	290.78
Tangible Book Value Per Share	-12.13	-23.31	33.00	76.25	138.64	127.97
Machinery	-	18.66	17.82	26.05	19.18	15.71
Construction In Progress	-	0.16	0.03	6.33	0.88	1.12
Leasehold Improvements	-	0.9	0.88	50.14	50.13	49.03

Source: S&P Capital IQ. Standard template. Financial Sources.